A study to see the surgical outcomes and how safe and effective is the new laser machine MEL 90

A study of safety, efficacy and refractive outcomes of MEL 90 excimer laser platform - MEL 90

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2014/09/005061

Enrollment

100

Registered

2014-09-25

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Patients with Myopia, Hypermetropia and Astigmatism undergoing treatment on the MEL 90 excimer laser platform

Interventions

Intervention1: PRK (PHOTO REFRACTIVE KERATECTOMY): Under topical anaesthesia, a 9mm well will be applied firmly to the corneal surface, centered on the visual axis, and filled with 20% ethanol in bala

the cornea washed with Balanced Salt Solution (BSS). The loose epithelium is then scraped off using a sponge bud. Eximer laser ablation will then be carried out using the MEL 90 excimer laser platform

Eligibility

Inclusion criteria

Inclusion criteria: •Any gender, 21 to 40 years of age •Stable corneal conditions within the last 12 months •Stable refraction since past 12 months ( •Healthy ocular surface with stable tear film •Discontinuation of Soft contact lenses 1 week, and rigid contact lenses 3 weeks prior to surgery •For myopia correction, myopia upto -10 Diopters •For hyperopia correction, hyperopia upto + 3 Diopters •For astigmatic correction, astigmatism upto 3 Diopters

Exclusion criteria

Exclusion criteria: •Thin corneas (Corneal pachymetry •Steep corneas Kmax >48 D •Keratoconus suspects or frank keratoconus •Moderate to severe dry eye (Shirmers1 •Socket / globe /lid anomalies â?? very deep set eyes, nanophthalmos •Severe meibomian gland disease, lid abnormalities •Severe atopy •Contact lens overuse •Pregnant and nursing mother •Autoimmune disorders •Pts on systemic medications eg Iso retinoic acid, hormonal preperations, OCPs, antidepressants.

Design outcomes

Primary

Measure	Time frame
To evaluate the efficacy, safety and refractive outcomes of MEL 90 Excimer laser platform.Timepoint: 6 MONTHS	—

Secondary

Measure	Time frame
NOT APPLICABLETimepoint: NOT APPLICABLE	—

Countries

India

Contacts

Public ContactDR SRI GANESH

NETHRADHAMA SUPERSPECIALITY EYE HOSPITAL

utsav_5093@yahoo.com09901903149

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026